Stockhouse.com: Taking it to the street
Latest Broadcasts
STKH
Internet/Technology
V.UNR
BASIC MATERIALS - METALS & MINING
V.PTV
BASIC MATERIALS - ENERGY
TPIM
Healthcare
V.MNV
Natural Resources
V.TMM
Basic Materials - Metals & Mining
An excellent place to start your search for new investments!
add to favorites print

Drug maker with successful anti-biotic seeks partner.

MiddleBrook Pharmaceuticals (NASDAQ: MBRK, Stock Forum) posted a quarter with complex financial results.

MiddleBrook reported first quarter 2008 revenue of $2.4 million compared to $1.8 million in the first quarter of 2007.  The net loss was $13.8 million for the first quarter, compared to a net loss of $13.7 million in the first quarter of 2007. But, the loss was not entirely operational. MBRK recorded a $7.4 million noncash warrant expense for the period.

The market did not seem to mind. The shares hit $3.85, with a 15% increase on Friday alone.

Middlebrook continued to do well selling its 750 mg strength Keflex capsules. It also received FDA approval of a New Drug Application for its once-daily amoxicillin PULSYS® product. There is no reasonable estimate of how much revenue this will bring in over the next year or two.

Middlebrook raised almost $20 million in the first quarter and also retained Morgan Stanley to find a partner or buyer for the company. Right now MBRK has enough cash to operate for a year.

If the firm does not find a buyer, these shares will collapse.

ABOUT THE AUTHOR
From the news desk of 24/7 Wall St.

This report was prepared by 24/7 Wall St., LLC exclusively for Stockhouse. 

 
print
 
Stockhouse Conflict and Disclosure Policy:

Stockgroup Media Inc., owners and operators of Stockhouse.com, has established the following rules to ensure that there is no appearance of impropriety on the part of any Stockhouse Editorial writers ("Writers"). The content of Stockhouse Editorial articles (the "Articles") are the opinion of the Writer and any reliance on the content of these articles is at your sole risk. Our Writers are not registered investment advisors. You should not make any kind of investment decision in relation to Articles or stocks discussed in them without obtaining advice from a registered investment advisor.

Facts relied upon by our Writers are generally provided by the subject companies or gathered by our Writers from other public and/or private sources. These facts may be in error and if so, the opinions of our Writers may be materially different.

Writers may own, buy, or sell shares in public companies mentioned in their Articles, but in the Article they must prominently state their ownership position. Thus, a conflict may exist. Writers are not permitted to write Articles that attempt to benefit persons connected to the Writer, such as family or friends, except where disclosure is made in the same way as if the Writer him/herself owns stock.

Writers cannot solicit, accept, or agree to receive anything of value given or paid with the intent of influencing their Articles.

Stockhouse notifies each Writer about these rules, and we rely on the integrity of our Writers to ensure that our rules are followed.

 
FREE REPORTS
 
SPONSORED NEWS LINKS
 
 
 
 
Today's Feature  
 
ESO URANIUM CORPORATION
ESO Uranium Corp. ("the Company") has over 982,800 acres of prospective uranium claims distributed throughout the Athabasca Basin located in Northern Saskatchewan. The company also controls (100%) the Mikwam Gold Project in Northern Ontario totaling 26,885 acres which is the Western extension of the Casa Berardi Deformation Zone. Western Athabasca Basin: The company is conducting exploration on over 360,000 acres in the western Athabasca Basin, including the Cluff Pr...